| 4.55 0.48 (11.79%) | 07-01 14:30 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.78 | 1-year : | 6.54 |
| Resists | First : | 4.95 | Second : | 5.59 |
| Pivot price | 4.36 |
|||
| Supports | First : | 3.9 | Second : | 3.24 |
| MAs | MA(5) : | 4.28 |
MA(20) : | 4.37  |
| MA(100) : | 6.48 |
MA(250) : | 5.93 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 37 |
D(3) : | 32.5 |
| RSI | RSI(14): 48.3 |
|||
| 52-week | High : | 11.88 | Low : | 2.14 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ KLRS ] has closed below upper band by 27.4%. Bollinger Bands are 71.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.35 - 4.37 | 4.37 - 4.4 |
| Low: | 3.84 - 3.86 | 3.86 - 3.89 |
| Close: | 4.02 - 4.07 | 4.07 - 4.12 |
Kalaris Therapeutics Inc. operates as a pharmaceutical enterprise. The company's core mission centers on developing innovative cell therapies. These treatments are designed to reactivate the body's inherent immunity against critical, virus-linked diseases, especially in patients with profoundly compromised immune systems.
Tue, 30 Jun 2026
Price to book forward of Kalaris Therapeutics, Inc. – NASDAQ:KLRS - TradingView
Mon, 29 Jun 2026
Kalaris Therapeutics, Inc.(NasdaqGM:KLRS) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Fri, 26 Jun 2026
Kalaris Therapeutics, Inc. Actuals & Estimates (NASDAQ:KLRS) - TradingView
Tue, 23 Jun 2026
Kalaris to present Phase 1a data on retinal drug at ASRS meeting - Investing.com
Tue, 23 Jun 2026
Kalaris Therapeutics to Present Phase 1a Data for TH103 at ASRS 2026 Annual Meeting - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 24 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 8.8 (%) |
| Held by Institutions | 77.8 (%) |
| Shares Short | 763 (K) |
| Shares Short P.Month | 804 (K) |
| EPS | -0.78 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.98 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -28 % |
| Return on Equity (ttm) | -66.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -43 (M) |
| Levered Free Cash Flow | -27 (M) |
| PE Ratio | -5.78 |
| PEG Ratio | 0 |
| Price to Book value | 1.51 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.52 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|